Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab | Zendy

Jeroen de Filette | Zendy; Yanina Jansen | Zendy; Max Schreuer | Zendy; Hendrik Everaert | Zendy; Brigitte Velkeniers | Zendy; Bart Neyns | Zendy; Bert Bravenboer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

Author(s) -

Jeroen de Filette,

Yanina Jansen,

Max Schreuer,

Hendrik Everaert,

Brigitte Velkeniers,

Bart Neyns,

Bert Bravenboer

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-2300

Subject(s) - medicine , pembrolizumab , thyroid , thyroiditis , levothyroxine , thyroid function , anti thyroid autoantibodies , thyroid function tests , autoimmune thyroiditis , gastroenterology , autoantibody , endocrinology , cancer , immunology , antibody , immunotherapy

Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research